A new nanocarrier has been developed that is able to selectively deliver medicines to damaged cells in the lungs, alleviating fibrosis in mice, a study reports.

Based on a naturally occurring process called cell senescence, the system also helps reduce the therapies’ toxic effects on healthy cells, and represents a promising technology for the treatment of conditions such as pulmonary fibrosis and cancer.

“This nano-carrier may pave the way for new therapeutic approaches for serious conditions, such as pulmonary fibrosis or to eliminate chemotherapy-induced senescent cells,” Manuel Serrano, PhD, senior author of the study and a Catalan Institution for Research and Advanced Studies researcher at the Institute for Research in Biomedicine in Barcelona, said in a press release.